All In Biotech

Drug Trial Radar · NCT02550067

The Evidence for Contraceptive Options and HIV Outcomes Trial

A Multi Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women Using Depot Medroxyprogesterone Acetate (DMPA), Levonorgestrel (LNG) Implant, and Copper Intrauterine Devices (IUDs)

Last checked: Nov 19, 2026Latest source record: Aug 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 7,830 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,830

Actual

Start

Dec 14, 2015

Primary completion

Oct 31, 2018

Study completion Oct 31, 2018

Sponsor

Lead sponsor
FHI 360Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Washington; Wits Reproductive Health and HIV Institute; World Health Organization; Madibeng Centre for Research; Maternal Adolescent and Child Health Research; Qhakaza Mbokodo Research Clinic; The Aurum Institute NPC; Effective Care Research Unit; Emavundleni Research Centre; Setshaba Research Centre; University of North Carolina, Chapel Hill; Family Life Association of Swaziland; Columbia University; Kenya Medical Research Institute
First posted
Sep 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
Female only, from 16 years, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The ECHO Study is an open-label randomized clinical trial that will compare three highly effective, reversible methods of contraception (including a non-hormonal method) to evaluate whether there is a link between use of any of these methods and increased risk of acquiring HIV infection. A randomized clinical trial among about 7,800 women in four countries, ECHO will deliver evidence to support and guide individual, policy and programmatic decisions on contraception for women at risk of acquiring HIV infection.

Conditions

  • HIV
  • Contraception

Interventions

  • DMPADrug

    Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.

  • LNGDrug

    Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.

  • Copper IUDDrug

    Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare risks of HIV acquisition between women randomized to DMPA, LNG and copper IUDTime frame: From enrollment to 18 months

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • FLAS/ICAP Clinic 1& Clinic 2

    Manzini, Eswatini

  • Kisumu East Research Care and Training Program

    Kisumu, Kenya

  • Madibeng Centre for Research

    Brits, South Africa

  • Emavundleni Research Centre

    Cape Town, South Africa

  • MatCH Research Unit Commercial City

    Durban, South Africa

  • Effective Care Research Unit (ECRU) Frere Maternity Hospital

    East London, South Africa

  • Wits Reproductive Health and HIV Institute (WRHI)

    Johannesburg, South Africa

  • Aurum Klerksdorp Gavin Churchyard Legacy Centre

    Klerksdorp, South Africa

  • QM ladysmith

    Ladysmith, South Africa

  • MatCH Research Unit Edendale

    Pietermaritzburg, South Africa

  • Setshaba Research Centre

    Soshanguve, South Africa

  • University Teaching Hospital, Lusaka, Zambia

    Lusaka, Zambia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.